Company intelligence / Profile preview

Ardana

Edinburgh, Scotland, United Kingdomtrial.medpath.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Ardana was a pharmaceutical company focused on human reproductive health. Its lead compound Teverellix was in phase IIa development for BPH and endometriosis. The company was unable to successfully develop its compounds and operations were discontinued in 2008.

Therapeutic areas: CardiovascularMen's HealthEndocrinologyWomen's HealthOncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ARD-0403

Phase 3

Indications: Hypogonadism

Partnerships

Medical Research Council's Human Reproductive Sciences Unit (HRSU)

Beyond the preview

Go deeper on Ardana.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ardana.

Explore the full profile